A New Era Of Scrutiny For China-Linked Pharma Deals
Introduced in the U.S. House of Representatives on June 2, the Biotech Investment National Security Act represents a bipartisan attempt to expand U.S. outbound transaction controls....To view the full article, register now.
Already a subscriber? Click here to view full article